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LETTER TO THE EDITOR
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Introduction
Pancreatic adenocarcinoma (PC) is diagnosed as a locally
advanced or borderline resectable disease in up to 40% of
patients [1]. In nonmetastatic patients who are not eligible
for upfront surgical treatment, multiple-agent chemotherapy
is recommended [2] in order to select candidates for treat-
ment intensification with radiotherapy as exclusive local
treatment or as a neoadjuvant treatment before surgery
[3–5]. In recent years, stereotactic body radiotherapy (SBRT)
emerged as a promising alternative to conventional chemo-
radiation [6]. Results from phase I/II trials [7] reported a
cumulative local control rate of 71% at 1 year, and benefit of
SBRT is currently evaluated in prospective phase III trials [8].
Moreover, irradiation up to 50Gy in five fractions to part of
the tumor has been correlated with an increase in local con-
trol and R0 resection rate, suggesting a potential interest of
dose escalation to improve global outcome and disease
downstaging in order to achieve surgical resectability [9,10].
However, development of more aggressive treatment sched-
ules is limited by proximity of critical dose-limiting structures
(duodenum, stomach, bowel), often resulting in a stringent
tradeoff between adequate coverage of the target volume
and preservation of dose constraints of the organs at risks
(OARs). It has been shown that large inter-fractional physio-
logical modifications in shape and position of OARs may
occur, influencing daily dose distribution [11]. Determination
of OAR motion on daily basis may be useful to improve crit-
ical structures protection while safely increasing dose to the
target [12,13]. The aim of our study was to evaluate the per-
formance of daily anatomical assessment to predict acute
toxicity from abdominal SBRT in a prospective cohort of
patients with locally advanced PC.
Material and methods
Study population and treatment protocol
Patients with locally advanced nonmetastatic PC were
included in a prospective phase II single arm study testing
SBRT following response or stable disease after eight cycles
of FOLFIRINOX chemotherapy. The study was conducted
according to the principles of the Declaration of Helsinki and
was approved by Institutional Review Board with the number
NL49643.078.14. Informed consent to the study procedures
was signed by the patients. Before treatment initiation, fidu-
cial markers were inserted in the tumor via endoscopic ultra-
sonography guidance. Gross tumor volume (GTV) was
contoured on a 1.5-mm thick contrast-enhanced CT scan.
Clinical target volume (CTV) included the GTV plus geometric
expansion of 5mm to include potential microscopic tumor
extension. Planning target volume (PTV) encompassed the
CTV plus a 2mm margin. Prescription dose to the 80% iso-
dose line of the PTV was 40Gy in 8Gy daily fractions. At
least 95% of the prescribed dose should cover 95% of the
PTV, though PTV could be underdosed to meet the con-
straints of dose-limiting OARs. In particular, dose constraint
for stomach, duodenum and bowel consisted of a maximum
point dose (Dmax) of 35Gy, while spinal cord and liver were
allowed to receive a Dmax of 27.5 Gy and less than 20Gy to
a volume inferior to 700 cc, respectively. Dose constraints are
summarized in Supplementary Table 1a. Fiducial tracking
was performed using the Synchrony respiratory motion track-
ing system. Clinical evaluation with physical examination and
CT scan was performed at 1, 3 and 6months, and subse-
quently once a year until 5 years after the treatment or until
disease progression. According to study protocol, assessment
of acute toxicity (occurring within 3months from the first
day of treatment) was prospectively performed at pre-speci-
fied time points (2weeks, 1 month and 3months) using the
Common Terminology Criteria for Adverse Events (CTCAE
V4.03, 2010).
System description and evaluation of daily dose
Detailed description of the system and clinical application for
daily dose evaluation has been previously reported [12,14].
In summary, in our institution, a treatment platform integrat-
ing a CyberKnife with a CT scanner on-rail allows to perform
daily imaging before irradiation. According to the LAPC-1
protocol, for the first three fractions of the treatment, an
end-expiration CT scan with IV contrast was acquired in
treatment position and was used for comparison. Daily CT
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scans were matched offline to the planning CT by applying a
rigid registration based on spine match followed by a fidu-
cials match correction, which was used to overlay the
planned dose distribution on the daily CT after OAR delinea-
tion according to RTOG recommendations, as previously
described [12,14].
Data analysis
For each organ, the following metrics were extracted: volume
receiving at least 35Gy (V35, in cc), maximum dose received
by 2 cc (D2, in Gy), maximum dose received by 5 cc (D5, in
Gy), maximum dose received by 10 cc (D10, in Gy), and the
maximum point dose to a single voxel (Dmax, in Gy). Three
sets of value were collected, corresponding, respectively, to
the parameter value as extracted from the simulation CT-
based DVH (‘planned’), to the average of each DVH param-
eter value after dose over the three daily CT scans (‘daily’)
and to the highest value reached on one of the daily CT
scans (‘peak’). For each OAR, correlation between planned,
daily and peak values and specific acute toxicities (abdominal
pain, nausea, diarrhea) was assessed using median compari-
son with the Kruskall–Wallis test. A receiver operating curve
(ROC) was subsequently plotted to assess the performance
of planned, daily and peak parameters to predict acute tox-
icity. An area under the curve (AUC) > 0.7 indicated moder-
ate-high accuracy. The optimal cutoff value in terms of
sensitivity and specificity was obtained based on Youden-J
index, corresponding to the dose or volume level for whom
the maximum vertical distance between the ROC curve and
the diagonal line was found [15].
Results
Overview
A prospective cohort of 39 patients underwent SBRT within
the LAPC1 trial. Daily CT scans were not available for 4
patients due to logistics and therefore 35 patients (19 head
and 16 body tumors) were included in the study. Median
age was 61 years (range 48–75). Median tumor diameter was
38mm (range 19–70), corresponding to a median GTV size of
26.8 cc (range 5.1–141.0 cc): 31% of patients experienced a
partial response following induction chemotherapy (See
Supplementary Table 1b for patient and tumor characteris-
tics). All patients received the entire planned treatment
course without interruption and were evaluated at 15 days, 1
and 3months for toxicity according to study plan. Within
3months from the beginning of the treatment, 22 (63%)
patients experienced acute treatment-related Grade 1–2 tox-
icity. This consisted of nausea in 11 patients, abdominal pain
in 15 patients and diarrhea in 4 cases. Severity was mild,
consisting of 12 Grade 1 and 18 Grade 2 toxicities. No Grade
3 acute toxicity was observed (See Supplementary
Table 1c).
Acute nausea
No difference was found at median comparison for dose
parameters in stomach and bowel between patients with or
without acute nausea (Supplementary Table 2). Conversely,
dose distribution to duodenum was correlated to the onset
of acute nausea: significantly higher median values were
found in patients experiencing acute nausea compared to
asymptomatic patients (Table 1 and Supplementary Table
2a). At ROC curve calculation, planned (D2, D5, D10, Dmax),
daily (V35, D2, D5, D10) and peak (V35, D2, D5, D10) values
showed an AUC >0.7 (Supplementary Figures 1 and 4).
However, at a dose threshold of 32.2 Gy, daily D2 yielded the
highest accuracy (J: 0.62) compared to its planned and peak
counterpart (J: 0.57 and 0.48, for 30.5 and 33.2 Gy respect-
ively) (Figure 1(a) and Supplementary Table 3).
Acute abdominal pain
At median comparison, only dose parameters related to the
stomach were associated with the presence of abdominal
pain: in particular higher median planned (Dmax, D5, D10),
daily (D2, D5, D10) and peak (D2, D5, D10) parameters were
found significant (Table 1, Supplementary Table 2b). ROC
curve calculation showed for each value an AUC >0.7
(Supplementary Table 3, Supplementary Figures 2 and 5).
Comparable accuracy (J: 0.48) was found for planned and
daily D10 at a dose threshold of 16.6 and 22.1 Gy, respect-
ively (Figure 1(b) and Supplementary Table 3).
Acute diarrhea
No differences were found between patients with or without
treatment-related diarrhea at median comparison for dose
parameters related to stomach and duodenum
(Supplementary Table 2a and b). Only median plan D10, daily
D5, daily D10 and peak D10 to the bowels were significantly
higher in patients with diarrhea compared to asymptomatic
patients (Table 1 and Supplementary Table 2c). At ROC curve
calculation, median plan D10, daily D5, daily D10 and peak
D10 showed an AUC >0.8 (Supplementary Figures 3 and 6).
Daily D10 yielded the highest accuracy (J: 0.71) at a thresh-
old of 16.9 Gy (Figure 1(c) and Supplementary Table 3).
Discussion
Gastrointestinal acute toxicity is a frequent occurrence during
radiation therapy of the upper abdomen, with important
consequences in terms of global tolerability and compliance
to treatment [16–18]. Most importantly, it may affect radio-
therapy treatment planning, limiting the radiation dose that
can be safely delivered [17]. Use of fractionated schedules
reduced incidence of major toxicities from 42% in pivotal tri-
als of single-fraction SBRT [19] to less than 10% in modern
series using hypofractionated regimens [20,21]. In our experi-
ence, only minor acute G1–2 toxicities were observed, con-
firming that 40Gy in 5 fractions is a feasible and well-
tolerated dose schedule. However, long-term follow-up is
2 M. LOI ET AL.
Table 1. Median comparison (Kruskall–Wallis Test) for selected parameters between patients with or without acute toxicity
following SBRT.
Duodenum Acute nausea (median [IQR]) No acute nausea (median [IQR]) p
Planned V35 0.1 [0.0–0.30] cc 0.0 [0.0–0.20] cc .07
D2 32.6 [31.9–33.9] Gy 26.7 [19.2–31.5] Gy .021
D5 30.5 [29.4–32.8] Gy 21.4 [16.5–29.3] Gy .021
D10 26.4 [25.5–30.6] Gy 18.8 [12.1–26.3] Gy .009
Dmax 36.4 [36.1–37.6] Gy 35.8 [33.1–37.1] Gy .045
Daily V35 0.9 [0.7–1.5] cc 0.3 [0.1–1.1] cc .025
D2 33.5 [33.1–34.2] Gy 28.7 [23.8–32.5] Gy .007
D5 31.0 [29.5–33.0] Gy 24.3 [19.5–30.7] Gy .008
D10 27.1 [24.5–31.1] Gy 19.9 [15.3–27.4] Gy .014
Dmax 41.3 [39.8–41.9] Gy 38.5 [36.4–41.9] Gy .08
Peak V35 1.4 [1–2.3] cc 0.4 [0.1–2.1] cc .04
D2 34.5 [33.8–36.0] Gy 31.7 [24.6–35.3] Gy .04
D5 32.3 [31.2–34.5] Gy 25.2 [20.6–31] Gy .005
D10 28.7 [26.5–31.5] Gy 20.9 [16.7–28.5] Gy .01
Dmax 42.1 [41.7–46.1] Gy 41.9 [38.5–45.5] Gy .3
Stomach Acute pain (median [IQR]) No acute pain (median [IQR]) p
Planned V35 0.1 [0.0–0.4] cc 0.0 [0.0–0.2] cc .11
D2 31.9 [27.3–32.9] Gy 25.8 [15.6–32.3] Gy .06
D5 29.3 [24.6–30.9] Gy 20.5 [14.0–29.6] Gy .023
D10 25.6 [20.1–29] Gy 16.3 [12.9–25.1]Gy .012
Dmax 36.8 [35.2–38.4] Gy 35.7 [26–36.8] Gy .029
Daily V35 0.3 [0.0–0.9] cc 0.7 [0.2–2.1] cc .17
D2 32.5 [28.5–35] Gy 27.9 [18.9–32.8] Gy .016
D5 29.0 [25.2–31.7] Gy 22.7 [16.6–29] Gy .012
D10 26.0 [21.1–28.5] Gy 18.7 [14.8–23.6] Gy .005
Dmax 39.1 [30.4–40.5] Gy 38.3 [36.6–42.3] Gy .40
Peak V35 1.8 [0.4–3.2] cc 0.6 [0.0–1.4] cc .08
D2 34.7 [29.4–36.5] Gy 31.0 [20.9–34.5] Gy .034
D5 32.1 [25.7–33.4]Gy 26.2 [17.3–31.1] Gy .01
D10 28.9 [22.3–30.9]Gy 20.9 [15.4–25.8] Gy .05
Dmax 41.4 [37.0–45.9] Gy 41.2 [33.3–43.7]Gy .32
Bowel Acute diarrhea (median [IQR]) No acute diarrhea (median [IQR]) p
Planned V35 0.0 [0.0–0.0] cc 0.0 [0.0–0.1] cc .21
D2 28.0 [22.7–31.2] Gy 18.8 [13.5–27.5] Gy .09
D5 25.2 [21.3–27.9] Gy 16.7 [11.8–23.1] Gy .07
D10 23.1 [20.0–24.9] Gy 15.1 [9.7–20.6] Gy .034
Dmax 35.3 [32.1–37.4] Gy 31.1 [20.9–36.2] Gy .23
Daily V35 0.7 [0.1–1.5] cc 0.0 [0.0–0.2] cc .13
D2 29.8 [24.3–32.6] Gy 16.9 [14.9–26.2] Gy .07
D5 27.0 [22.3–29.5] Gy 19.0[12.5–22.2] Gy .038
D10 24.2 [20.4–26.4] Gy 14.6 [9.8–19.3] Gy .027
Dmax 36.6 [31.4–39.9] Gy 32.1 [22.2–38.7] Gy .22
Peak V35 1.2 [0.3–3.4] cc 0.0 [0.0–0.6] cc .12
D2 33.5 [26.8–37.6] Gy 22.7 [16.8–28.8] Gy .07
D5 18.8 [13.1–24.2] Gy 30.7 [24.2–33.8] Gy .043
D10 16.5 [10.9–21.1] Gy 27.3 [21.6–29.7] Gy .031
Dmax 41.8 [35.0–45.0] Gy 35.9 [27.2–43.1] Gy .35
For extended analysis refer to Supplementary Table 2s. IQR: inter-quartile range.
Values reaching statistical significance (p< 0.05) are indicated in bold.
Figure 1. Dot chart summarizing relevant dose parameters for toxicity. Each patient is represented by a white dot; bar represent the value associated with Youden
J. (A) Daily D2 to duodenum in patients with with (right) or without (left) acute nausea. (B) Daily D10 to stomach in patients with (right) or without (left) abdominal
pain. (C) Daily D10 to bowel in patients with (right) or without (left) acute diarrhea.
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needed to confirm that these doses aresafe for late toxicity.
More intensive dose regimens, delivering higher biological
doses, may be of interest to increase response rate [10]:
however due to proximity of radiosensitive critical structures,
further dose escalation may expose to higher risk of adverse
severe events. Moreover, initial experiences of daily imaging
with cone-beam CT [22] and more recent trials implementing
the use of high-definition imaging such as integrated MRI or
helical CT suggest that large inter-fractional variations in
shape and position occurs during the treatment course
[12,13,23], thus adding further uncertainty in determining
the tolerance of OARs to radiation injury, since deformation
and movement may allow critical structure to approach
higher dose regions [12]. Hence, there is an urgent need to
develop strategies to predict the risk of overirradiation of
OARs and possibly compensate for uncertainties due to
organ motion. In the present study dose estimates calculated
from daily parameters (duodenum daily D2, stomach daily
D10 and bowel daily D10), yielded superior accuracy in pre-
dicting acute toxicity. This finding has important implications,
since daily assessment using high-quality diagnostic imaging
provided more accurate prediction of clinical toxicities than
exclusive simulation CT-based planning and may allow to
prevent unintended dose constraints violation favored by
organ motion. Daily dose recalculation at the means of hel-
ical CT or MRI may be applied to dose adaption based on
daily assessment of anatomic variations [14,24]. Initial clinical
application could be online evaluation of dose distribution to
the organ at risk in order to aid clinical decision before treat-
ment delivery in case of large inter-fractional variations that
cannot be compensated by setup correction [13,14].
Secondarily, development of daily adaptive protocols
could be implemented: for example, selection of the plan
(from a library of previously generated treatment plans or
after full replanning) that, according to the anatomy of the
day, allows the better therapeutic index between OAR spar-
ing and target coverage [22].
Finally, mitigation of the risk of excessive OARs irradiation
related to organ motion through daily imaging and dose
adaptation may permit safe dose escalation to increase
tumor control. In our cohort, dose thresholds for prediction
of acute toxicity elaborated from daily assessment (i.e. duo-
denum daily D2 and stomach daily D10) compared favorably
to their planned counterpart, resulting in concession of dose
to the OARs of þ1.7 and þ5.5 Gy, respectively, thus improv-
ing the tradeoff between tumor coverage and organ sparing.
These figures compare favorably with constraints enforced in
trials of five-fraction pancreatic SBRT, in which D1cc < 33Gy,
D3cc < 20Gy, and D9cc < 15Gy on stomach and small bow-
els were used [20]. Based on these results, an adaptive strat-
egy using daily imaging could be proposed to manage
uncertainty linked to organ motion and safely deliver higher
doses of radiation without increasing the risk for acute tox-
icity [24].
There are several limitations in our work. Since LAPC-1
was not specifically designed to test the benefit of daily
dose evaluation, according to study protocol only three daily
CTs out of five fractions have been acquired to limit
unnecessary irradiation and contrast product injection: future
trials specifically designed should address this issue. Acute
toxicity, consisting of moderate G1–2 complications, has
been used as endpoint to test the predictive value of daily
imaging, though constraints used for SBRT are mostly
designed to prevent dose limiting, potentially life-threatening
chronic side effects. Additional follow-up is needed to assess
the onset of late toxicities before further dose escalation can
be planned.
In conclusion, daily evaluation of dose to OAR using diag-
nostic-quality helical CT yields accurate prediction of acute
toxicity following SBRT for inoperable pancreatic carcinoma.
Its application in clinical practice may allow for implementa-
tion of image-guided dose adaptive strategies and safe
dose escalation.
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